Caris Life Sciences said its ultra-deep whole-genome sequencing assay, ChromoSeq, has secured MolDx coverage for myeloid malignancies. The company positioned the test for sensitive detection of clinically relevant genomic alterations, using ChromoSeq’s deep sequencing depth to support precision treatment decisions in hematologic oncology where comprehensive variant capture can be a gating factor for therapy access.